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Aim: The aim of this study was to investigate the role of a new inflammatory index (Colon
Inflammatory Index [CII]) as a predictor of prognosis and treatment efficacy in patients with
metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa
(Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT)+
bevacizumab or CT alone.
Patients and methods: Between November 14, 2007 and March 6, 2012, 276 patients diag-
nosed with CRC were available for baseline neutrophil-to-lymphocyte ratio (NLR) and lactate
dehydrogenase (LDH). We divided the population into three groups on basis of the CII index.
Results: At baseline in all populations, median PFS and OS was predictive of clinical
outcome (p<0.0001). Following adjustment for clinical covariates, multivariate analysis
confirmed CII index as an independent prognostic factor. The CII index was also predictive
when we evaluated the two distinct arms with (p=0.0009) or without bevacizumab
(p=0.0001). When we divided right side versus left side for treatment regimen (CT plus
bevacizumab versus only bevacizumab), we found a benefit of bevacizumab versus only CT
in the right side in patients treated with bevacizumab and not in patients treated with only
chemotherapy. Conversely, we found no difference the left side, but we found a difference in
the poor group of 4 months in favor to only chemotherapy.
Conclusion: Our results indicate that the CII index is a good prognostic marker for mCRC
patients in first line treatment with CT with or without bevacizumab.
Trial registration: NCT01878422 ClinicalTrials.gov; date of registration: June 7, 2013.
Keywords: metastatic colorectal cancer, bevacizumab, first-line, prognosis, lactate
dehydrogenase, neutrophil-to-lymphocyte ratio
Introduction
Colorectal cancer (CRC) is one of themajor causes of comorbidity and death from cancer
worldwide.1
Bevacizumab (B) is a monoclonal antibody that binds to the vascular endothe-
lial growth factor with antiangiogenic activity. The use of B combined with
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fluoropyrimidine-based chemotherapy (CT) plus oxali-
platin and/or irinotecan is considered standard of care in
first- and second-line treatment for patients with meta-
static CRC (mCRC).2,3
There are no current validated factors that can predict
sensitivity or resistance to B. Several studies have inves-
tigated this issue in recent years, but with poor results.
The literature has demonstrated the relationship
between systemic chronic inflammation and various types
of cancer, including CRC.4 The activation of the inflam-
mation by the tumor determines the inhibition of apoptosis
and can promote angiogenesis.5,6
Several papers in the literature have shown that neu-
trophil-to-lymphocyte ratio7-12 (NLR) and lactate dehydro-
genase (LDH)13–17 have a predictive and prognostic role in
various diseases, including CRC. We have previously
demonstrated in separate studies the correlation between
LDH serum levels18 and NLR19 and clinical outcome in
first-line mCRC. NLR is a good peripheral inflammatory
index and LDH serum levels are an indirect marker of
tumor hypoxia, neo-angiogenesis, metastasis development
and poor prognosis in many cancers.20
Based on these results, we have created a new inflam-
matory index (CII: colon inflammatory index), composed
of NLR and LDH. We considered CII as a predictor of
prognosis and treatment efficacy in patients with mCRC
enrolled in the prospective multicenter randomized ITACa
(Italian Trial in Advanced Colorectal Cancer)21 trial to
receive first-line CT+B or CT alone.
Patients and methods
The ITACa trial
The study population consisted of patients with advanced
CRC confirmed by pathological analysis. No patient had
received previous systemic therapy.
All eligible patients were randomly assigned in a 1:1
ratio to receive CT+B or CT alone as first-line therapy. CT
consisted of either FOLFOX4 or FOLFIRI at the clini-
cian’s discretion.18 The full protocol of the ITACa trial is
available in the first publication of the trial.21
Treatment continued until either progressive disease
(PD) or unacceptable toxicity or withdrawal of consent.
Tumor assessment was performed before the start of treat-
ment and repeated every 8 weeks until PD. Responses
were defined according to the Response Evaluation
Criteria in Solid Tumors (RECIST 1.1) guidelines (per
investigator assessment). The National Cancer Institute
Common Toxicity Criteria (NCI-CTC 3.0) were used for
evaluating adverse events.
All patients provided written informed consent
before enrollment in the study. The study was approved
by the local ethics committee (Comitato Etico Area
Vasta Romagna) on September 19, 2007, and registered
in our National Clinical Trials Observatory
(Osservatorio delle Sperimentazioni Cliniche) and in
the European Clinical Trials Database (EudraCT
no. 2007–004539-44) before patient recruitment began.
Registration on ClinicalTrials.gov (NCT01878422) was
not mandate and was completed at a later date after the
end of the study (June 7, 2013).
The study was carried out in accordance with the
Declaration of Helsinki under good clinical practice con-
ditions and after full approval from the ethics committees
of all participating centers.
Statistical analysis
The objectives of this secondary analysis were to examine
the association between baseline CII and progression-free
survival (PFS) and overall survival (OS) in the ITACa
study. CII was developed combining NLR and LDH.
Patients were divided into three risk groups depending
on their CII: good (0 factor: NLR <3 and LDH ≤upper
limit of normal-ULN), intermediate (1 factor: NLR ≥3 or
LDH >ULN) and poor (2 factors: NLR ≥3 and LDH
>ULN). The cutoff of NLR ≥3 was previously determined
(Passardi A et al, Oncotarget 2016) and the ULN for LDH
was defined according to the limit of each center (Passardi
A et al, PloSOne 2015).
PFS was defined as the time from random assignment
to the first documentation of PD (as per investigator
assessment), or death from any cause. Patients undergoing
curative metastasectomy were censored at the time of
surgery. OS was defined as the time between random
assignment and death or last follow-up visit.
Association between risk groups of CII and baseline
characteristics was tested using Chi-squared or Fisher
exact test. PFS, OS and their two-sided 95% CI were
estimated by the Kaplan–Meier method and curves were
compared by the log-rank test (at a significance level of
5%). Estimated HRs and their two-sided 95% CI were
calculated using the Cox-proportional hazard model. HRs
adjusted by center and baseline characteristics (gender,
age, performance status, KRAS status, tumor site [rec-
tum/colon], CT regimen [FOLFOX4/FOLFIRI] and
ITACa treatment [CT+B vs CT alone]) were calculated
Casadei-Gardini et al Dovepress
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using the Cox-proportional hazard model. Covariate selec-
tion was based on a list of suspected prognostic factors
derived from the ITACa study.
The ORR was classified into partial response (PR),
stable disease (SD) and PD. Either Chi-squared or Fisher's
exact test was used to evaluate the association between CII
and ORR. All p-values were based on two-sided testing,
and statistical analyses were performed using SAS statisti-
cal software version 9.4 (SAS Inc., Cary, NC, USA).
Results
Patient characteristics
Between November 14, 2007, and March 6, 2012, 276
patients diagnosed with CRC were available for baseline
NLR and LDH (Figure 1): 164 (59.4%) were males and 112
(40.6%) females with a median age at diagnosis of 66 years
(range 33–83). Median follow-up was 36 months (range
1–65). Overall, median PFS was 9.1 (95% CI 8.5–9.9)
and median OS was 21.4 months (95% CI 19.3–24.5).
We divided the population into three groups on the
basis of CII. The three groups of patients were compar-
able for age, gender, tumor site, KRAS status and ITACa
treatment. A considerable proportion of patients with
poor CII had a performance status 1–2 (Table 1).
Table S1 shows the characteristics of patients treated
with and without B.
CII and clinical outcome in all patients
Median PFS was 10.3 months (95% CI 9.3–13.1), 8.7
months (95% CI 6.9–10.3) and 7.3 months (95% CI
Figure 1 Flowchart of the study.
Abbreviation: CII, Colon Inflammatory Index.
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5.5–8.9) for patients with good, intermediate and poor CII,
respectively (p<0.0001) (Figure 2A). Median OS was 29.9
months (95%CI 24.3–37.3), 20.9 months (95%CI
16.8–25.4) and 14.4 months (95% CI 11.4–17.1) for
patients with good, intermediate and poor CII, respectively
(p<0.0001) (Figure 2B). The three categories were asso-
ciated with different toxicities (Table 2).
In multivariate analysis, CII showed an independent
prognostic factor predictive of PFS and OS after adjustment
for clinical covariates (ITACa treatment, center, CT regimen,
KRAS status and baseline characteristics) (Table 3).
CII classification was not associated with response
(Table 4).
CII and clinical outcome in patients
treated with CT+B
Among patients treated with CT+B, median PFS was 12.1
months (95% CI 9.8–14.7), 10.0 months (95% CI
6.9–12.9) and 8.6 months (95% CI 3.7–9.4) for patients
with good, intermediate and poor CII, respectively
(p=0.0004) (Figure 3A). Median OS was 31.6 months
Table 1 Baseline characteristics according to CII. Good (0 factor: NLR<3 e LDH≤UNL); intermediate (1 factor: NLR≥3 o LDH>UNL);
poor (2 factors: NLR≥3 e LDH>UNL)
Good (0 factor) Intermediate (1 factor) Poor (2 factors) Overall p
N=114, 41.3% N=98, 35.5% N=64, 23.2% N=276, 100%
n (%) n (%) n (%) n (%)
Median age (range) 66 (33–83) 65 (34–82) 65 (37–81) 66 (33–83) 0.877
Gender
Male 73 (64.0) 55 (56.1) 36 (56.2) 164 (59.4)
Female 41 (36.0) 43 (43.9) 28 (43.8) 112 (40.6) 0.254
ECOG PS
0 98 (86.0) 85 (86.7) 37 (57.8) 220 (79.7)
1–2 16 (14.0) 13 (13.3) 27 (42.2) 56 (20.3) <0.0001
Tumor localization
Rectum 30 (26.3) 27 (27.5) 15 (23.4) 72 (26.1)
Colon 84 (73.7) 71 (72.5) 49 (76.6) 204 (73.9) 0.732
Right-sided 65 (58.0) 68 (70.1) 44 (68.7) 177 (64.8)
Left-sided 47 (42.0) 29 (29.9) 20 (31.3) 96 (35.2) 0.102
Stage at diagnosis
I–III 36 (34.0) 24 (25.3) 6 (9.7) 66 (25.1)
IV 70 (66.0) 71 (74.7) 56 (90.3) 197 (74.9) 0.0006
Grade
1 5 (5.1) 3 (4.1) 4 (8.5) 12 (5.5)
2 68 (69.4) 45 (61.6) 25 (53.2) 138 (63.3)
3 25 (25.5) 25 (34.3) 18 (38.3) 68 (31.2) 0.263
CT regimen
FOLFOX4 71 (62.3) 59 (60.2) 41 (64.1) 171 (62.0)
FOLFIRI 43 (37.7) 39 (39.8) 23 (35.9) 105 (38.0) 0.877
KRAS statusa
Wild type 70 (61.4) 63 (64.3) 41 (64.1) 174 (63.0)
Mutated 44 (38.6) 35 (35.7) 23 (35.9) 102 (37.0) 0.688
ITACa treatment
CT+B 62 (54.4) 42 (42.9) 29 (45.3) 133 (48.2)
CT 52 (45.6) 56 (57.1) 35 (54.7) 143 (51.8) 0.171
Notes: aMandatory as consequence of amendment n. 1 of May 3, 2009.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ITACa, Italian Trial in Advanced Colorectal Cancer; CT, chemotherapy; B, bevacizumab; CII, Colon
Inflammatory Index; NLR, neutrophil-lymphocyte ratio; PS, performance status.
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(95% CI 22.3–41.7), 20.6 months (95% CI 13.6–27.0) and
12.7 months (95% CI 5.4–14.6) for patients with good,
intermediate and poor CII, respectively (p=0.0009)
(Figure 3B).
Following adjustment for the same clinical covari-
ates, multivariate analysis confirmed CII as an indepen-
dent prognostic factor for predicting PFS and OS
(Table 3).
CII and clinical outcome in patients
treated with CT alone
Median PFS was 9.6 months (95% CI 8.6–13.0), 8.4
months (95% CI 6.2–9.1) and 7.3 months (95% CI
4.5–9.0) for patients with good, intermediate and poor
CII, respectively (p=0.002) (Figure 4A). Median OS was
27.1 months (95%CI 20.8–38.7), 21.3 months (95%CI
16.8–28.0) and 17.1 months (95% CI 11.5–23.2) for
patients with good, intermediate and poor CII, respectively
(p=0.0001) (Figure 4B).
Following adjustment for the same clinical covari-
ates, multivariate analysis confirmed CII as an indepen-
dent prognostic factor for predicting PFS and OS
(Table 3).
CII and tumor site
For tumors located in the right side, median PFS was
10.4 months (95% CI 8.3–13.7), 7.7 months (95% CI
5.1–10.2) and 8.9 months (95% CI 1.0–10.3) for
patients with good, intermediate and poor CII, respec-
tively (p=0.002) (Table 5). Median OS was 26.4
months (95% CI 19.2–35.7), 15.0 months (95%CI
11.5–20.9) and 15.0 months (95% CI 2.4–24.5) for
patients with good, intermediate and poor CII, respec-
tively (p=0.004). Following adjustment for clinical
covariates (ITACa treatment, center, CT regimen,
KRAS status and baseline characteristics), multivariate
analysis confirmed CII as an independent prognostic
factor for predicting PFS and OS (Table 5).
For tumors located in the left side, median PFS was
10.3 months (95% CI 9.1–13.7), 9.1 months (95% CI
6.5–11.3) and 6.5 months (95% CI 3.7–8.8) for patients
with good, intermediate and poor CII, respectively
(p<0.0001). Median OS was 36.6 months (95% CI
24.8–44.4), 24.8 months (95% CI 19.3–28.0) and 13.7
months (95% CI 8.2–16.8) for patients with good, inter-
mediate and poor CII, respectively (p<0.0001).
Following adjustment for clinical covariates (ITACa
treatment, center, CT regimen, KRAS status and base-
line characteristics), multivariate analysis confirmed CII
as an independent prognostic factor for predicting PFS
and OS (Table 5).
When we considered left-sided and right-sided
tumors separately by treatment regimen (CT+B vs
CT alone), we observed a greater benefit of CT+B
than CT alone in patients with a right-sided tumor. In
particular, administration of CT+B yielded a 3-month
longer OS for the good-CII group of patients, whereas
a decrease in OS for the poor-CII group of patients.
Conversely, no difference was found in patients with
left-sided tumors, although the poor-CII group experi-
enced a 4-month longer OS with CT+B than with CT
alone (Table 6).
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Figure 2 Kaplan–Meier curves of progression free survival (PFS) (A) and overall survival (OS) (B) of patients for the Colon Inflammatory Index.
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Discussion
CII, based on NLR and LDH, allowed us to divide the
patient population treated in the ITACa study into three
categories: good, intermediate and poor. Good-CII
patients (114 out of 276) achieved a median PFS of
30 months vs 14 months for the poor-CII patients.
Interestingly, administration of CT+B resulted in
a 4-month longer OS than CT alone in good-CII
patients. The intermediate category of patients, how-
ever, showed no difference between the two regimens,
while B+CT administration proved detrimental for the
poor-CII group. When left-sided and right-sided tumors
Table 2 Association between Colon Inflammatory Index and toxicity
Grade Good Intermediate Poor p
n n n
Nausea 0 58 52 39
1–2 50 46 24
3–4 6 0 1 0.100
Vomiting 0 86 76 51
1–2 24 20 13
3–4 4 2 0 0.299
Diarrhea 0 57 43 43
1–2 47 50 19
3–4 10 5 2 0.034
Stomatitis 0 93 70 52
1–2 20 25 9
3–4 1 3 3 0.401
Fatigue 0 61 55 38
1–2 47 36 20
3–4 6 7 6 0.857
Anemia 0 96 78 47
1–2 18 17 15
3–4 0 3 2 0.045
Neutropenia 0 34 37 28
1–2 26 22 8
3–4 53 39 28 0.187
Thrombocytopenia 0 89 72 54
1–2 22 24 9
3–4 3 2 1 0.433
Febrile neutropenia 0 111 95 64
1–2 1 1 0
3–4 2 2 0 0.333
Hemorrhage 0 101 84 56
1–2 13 14 8
3–4 0 0 0 0.757
Hypertension 0 79 84 54
1–2 32 11 9
3–4 3 3 1 0.017
Thrombosis 0 92 85 48
1–2 6 5 8
3–4 16 5 8 0.905
Proteinuria 0 92 76 45
1–2 22 21 19
3–4 0 1 0 0.125
Neurologic system 0 69 65 45
1–2 35 28 16
3–4 10 5 3 0.126
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were considered separately, the good- and intermediate-
CII groups with left-sided tumors had a benefit of
almost 10 months compared to the right-sided tumors.
No difference was seen in the poor-CII category. By
assigning CT+B to right-sided tumors and CT alone to
left-sided tumors we observed that B has a greater
benefit in right-sided cancers, especially in CII-poor
patients. This could be explained by the different
tumor biology of the tumors classified according to
the CII. There are no important differences with the
data collected in the study. Unfortunately, we did not
have the data on the BRAF that might explain this
difference. The increased aggressiveness of tumors
classified as poor can be seen in Table 1, where 90%
of poor-CII tumors and only 66% of good-CII tumors
were metastatic at diagnosis. The lower response to
B in intermediate-CII and poor-CII patients can also
Table 4 Association between the Colon Inflammatory Index and
response
Good Intermediate Poor pa
n (%) n (%) n (%)
Overall
CR+PR 69 (46.9) 46 (31.3) 32 (21.8)
SD+PD 45 (35.2) 51 (39.8) 32 (25.0) 0.136
CT+B
CR+PR 37 (51.4) 21 (29.2) 14 (19.4)
SD+PD 25 (41.7) 20 (33.3) 15 (25.0) 0.530
CT
CR+PR 32 (42.7) 25 (33.3) 18 (24.0)
SD+PD 20 (29.4) 31 (45.6) 17 (25.0) 0.214
Notes: aAdjusted by ITACa treatment, center, CT regimen, KRAS status and baseline
characteristics.
Abbreviations: LIPI, lung immune prognostic index; CR, complete response; PR,
partial response; SD, stable disease; PD, progressive disease; ITACa, Italian Trial in
Advanced Colorectal Cancer; CT, chemotherapy; B, bevacizumab.
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Figure 3 Kaplan–Meier curves of PFS (A) and OS (B) for the Colon Inflammatory Index patients treated with CT +B.
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be explained with a high LDH value, which underlies
a hypoxic microenvironment. In hypoxia, Von Hippel
Lindau (VHL) suppressor dissociates from its hypoxia-
inducible factor-1 (HIF-1) subunit. HIF-1 once disso-
ciated allows the transcription of several gene targets
implicated in neoangiogenesis, including LDH.
The lower efficacy of B in poor-CII patients may be
attributable to a lower efficacy of the drug in inflam-
matory and hypoxic conditions, as for high NLR and
LDH levels. Inflammation is a common feature of
cancer and is due to several proinflammatory cytokines
such as TNF-alpha, IL-1, IL-6, reactive oxygen and
nitrogen species, prostaglandins and microRNAs,
which accumulate contributing to creating a pro-
tumorigenic microenvironment. A strong link between
inflammation and hypoxia has already been demon-
strated, with a series of common activators such as
HIFs and nuclear factor-κB (NF-κB).22,23 NF-kB is
activated in CRC in response to inflammation, promot-
ing tumorigenesis and cancer progression.24 A number
of NF-kB target genes, such as IL-8 and VEGF, are
known to be involved in the angiogenic process, and to
be also target of HIF-1 alpha, highlighting the exis-
tence of an intricate crosstalk between inflammation
and hypoxia in cancer cells.25 Hypoxia could be
responsible for a lower efficacy of B in these tumors,
as this condition has been known to induce resistance
to antiangiogenic treatments.22 We observed
a detrimental effect of B in poor-CII patients with
a right-sided tumor. Right-sided tumors have a series
of features associated with higher hypoxic and inflam-
mation conditions. Higher expression levels of COX-2
and eNOS, both markers associated with hypoxia,27,28
have been observed in patients with these tumors,26
Moreover, high frequency of microsatellite instability
(MSI), as well as elevated microsatellite alterations at
selected tetranucleotide repeats (EMAST) has been
observed in right-sided CRC compared to left-sided
ones.29,30 Both these markers are associated with
higher tumor inflammation and hypoxia.31,32
Although it is only a hypothesis, which must be
evaluated in future translational studies, CII based on
NLR and LDH could be an indirect index of tumor
hypoxia.
In conclusion, CII appears to be a good index for
identifying the prognosis of patients on first-line CT.
Furthermore, the data suggest a possible role of CII in
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the identification of patients who may have an advan-
tage from the use of B in first-line treatment.
Acknowledgments
This trial was partially supported by the Italian Medicines
Agency (Agenzia Italiana del Farmaco [AIFA]; research
grant no FARM6FJJAY). The study sponsor was involved
neither in the study design nor in the collection, analysis, and
interpretation of data. The study sponsor did not provide
writing support for the report. All authors had full access to
all the data in the study. The corresponding author had the
final responsibility to submit for publication.
The authors would like to thank Veronica Zanoni for edit-
ing the manuscript, and Angela Ragazzini, Monia Dall’Agata
(Meldola), Camilla Di Nunzio and Claudia Biasini (Piacenza),
Elisa Pettorelli (Modena), Britt Rudnas, Barbara Venturini
(Rimini), Giorgia Razzini and Antonella Pasqualini (Carpi),
Alessandra Piancastelli (Faenza), Bernadette Vertogen and
Federica Zumaglini (Ravenna) for participating in this study.
Author contributions
All authors contributed toward data analysis, drafting and
critically revising the paper, gave final approval of the version
to be published, and agree to be accountable for all aspects of
the work.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin.
2014;64(1):9–29. doi:10.3322/caac.21208
2. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bev-
acizumab versus FOLFIRI plus bevacizumab as first-line treatment of
patients with metastatic colorectal cancer: updated overall survival and
molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Lancet Oncol. 2015;16(13):1306–1315. doi:10.1016/S1470-2045(15)
00122-9
3. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line che-
motherapy combined with cetuximab or bevacizumab on overall sur-
vival in patients with KRAS wild-type advanced or metastatic
colorectal cancer: a randomized clinical trial. JAMA. 2017;317
(23):2392–2401. doi:10.1001/jama.2017.5254
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and
cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer- related in
ammation. Nature. 2008;454:436–444. doi:10.1038/nature07205
6. Ko E, Jung G. Positive association of long telomeres with the invasive
capacity of hepatocellular carcinoma cells.Biochem Biophys Res Commun.
2014;447:358–363. doi:10.1016/j.bbrc.2014.04.022
7. Casadei Gardini A, Scarpi E, Orlandi E, et al. Prognostic role of aspartate
aminotransferase-lymphocyte ratio index in patients with metastatic col-
orectal cancer: results from the randomized ITACa trial. Onco Targets
Ther. 2018;11:5261–5268. doi:10.2147/OTT.S166614
8. Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation
indicators and ALBI score to predict liver cancer in HCV-patients
treated with direct-acting antivirals. Dig Liver Dis. 2018. pii: S1590–
8658(18)30986–1. doi:10.1016/j.dld.2018.09.016
9. Casadei Gardini A, Conti F, Foschi FG, et al. Imbalance of neutro-
phils and lymphocyte counts can be predictive of hepatocellular
carcinoma occurrence in hepatitis c-related cirrhosis treated with
direct-acting antivirals. Gastroenterology. 2018;154(8):2281–2282.
doi:10.1053/j.gastro.2017.12.051
10. Casadei Gardini A, Scarpi E, Faloppi L, et al. Immune inflammation
indicators and implication for immune modulation strategies in
advanced hepatocellular carcinoma patients receiving sorafenib.
Oncotarget. 2016;7(41):67142–67149.
11. Bruix J 1, Cheng AL 2, Meinhardt G, et al. Prognostic factors and
predictors of sorafenib benefit in patients with hepatocellular carci-
noma: analysis of two phase III studies. J Hepatol. 2017;67
(5):999–1008. doi:10.1016/j.jhep.2017.06.026
12. Lué A, Serrano MT, Bustamante FJ, et al. Neutrophil-to-lymphocyte
ratio predicts survival in European patients with hepatocellular carci-
noma administered sorafenib. Oncotarget. 2017;8(61):103077–-
103086. doi:10.18632/oncotarget.21528
13. Giampieri R, Puzzoni M, Daniele B, et al. First-line FOLFIRI and
bevacizumab in patients with advanced colorectal cancer prospec-
tively stratified according to serum LDH: final results of the GISCAD
(Italian Group for the Study of Digestive Tract Cancers) CENTRAL
(ColorEctalavastiNTRiAlLdh) trial. Br J Cancer. 2017;117
(8):1099–1104. doi:10.1038/bjc.2017.234
14. Fanotto V, Cordio S, Pasquini G, et al. Prognostic factors in 868 advanced
gastric cancer patients treated with second-line chemotherapy in the real
world. Gastric Cancer. 2017;20(5):825–833. doi:10.1007/s10120-016-
0681-6
15. Faloppi L, Bianconi M, Memeo R, et al. Lactate dehydrogenase in
hepatocellular carcinoma: something old, something new. Biomed
Res Int. 2016;2016:7196280. doi:10.1155/2016/7196280
16. Faloppi L, Del Prete M, Casadei Gardini A, et al. The correlation
between LDH serum levels and clinical outcome in advanced biliary
tract cancer patients treated with first line chemotherapy. Sci Rep.
2016;11(6):24136. doi:10.1038/srep24136
17. Faloppi L, Bianconi M, Giampieri R, et al. The value of lactate
dehydrogenase serum levels as a prognostic and predictive factor
for advanced pancreatic cancer patients receiving sorafenib.
Oncotarget. 2015;6(33):35087–35094. doi:10.18632/oncotarget.5197
18. Passardi A, Scarpi E, Tamberi S, et al. Impact of pre-treatment lactate
dehydrogenase levels on prognosis and bevacizumab efficacy in
patients with metastatic colorectal cancer. PLoS One. 2015;10(8):
e0134732. doi:10.1371/journal.pone.0134732
19. Passardi A, Scarpi E, Cavanna L, et al. Inflammatory indexes as
predictors of prognosis and bevacizumab efficacy in patients with
metastatic colorectal cancer. Oncotarget. 2016;7(22):33210–33219.
doi:10.18632/oncotarget.8901
20. Kolev Y, Uetake H, Takagi Y, et al. Lactate dehydrogenase-5
(LDH-5) expression in human gastric cancer: association with
hypoxia-inducible factor (HIF-1) pathway, angiogenic factors pro-
duction and poor prognosis. Annals of Surgical Oncology. 2008;15
(8):pp. 2336–2344. doi:10.1245/s10434-008-9955-5
21. Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevaci-
zumab added to standard chemotherapy in metastatic colorectal
cancer: nal results for rst-line treatment from the ITACa rando-
mized clinical trial. Ann Oncol. 2015;26:1201–1207. doi:10.1093/
annonc/mdv383
22. D’Ignazio L, Batie M, Rocha S. Hypoxia and inflammation in cancer,
focus on HIF and NF-κB. Biomedicines. 2017;5(2):pii: E21.
23. Cuomo F, Coppola A, Botti C, et al. Pro-inflammatory cytokines
activate hypoxia-inducible factor 3α via epigenetic changes in
mesenchymal stromal/stem cells. Sci Rep. 2018;8(1):5842.
doi:10.1038/s41598-018-24221-5
Dovepress Casadei-Gardini et al
Cancer Management and Research 2019:11 submit your manuscript | www.dovepress.com
DovePress
4367
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
82
.1
68
.1
3 
on
 1
3-
Ju
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
24. Wang S, Liu Z, Wang L, Zhang XN. F-kappaB signaling pathway,
inflammation and colorectal cancer. Cell Mol Immunol. 2009;6
(5):327–334. doi:10.1038/cmi.2009.33
25. Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and
response to antiangiogenic therapy in metastatic colorectal cancer.
Oncotarget. 2016;7(29):46678–46691. doi:10.18632/oncotarget.v7i29
26. Ulivi P, Scarpi E, Chiadini E, et al. Right- vs. left-sided metastatic
colorectal cancer: differences in tumor biology and bevacizumab
efficacy. Int J Mol Sci. 2017;18(6). doi:10.3390/ijms18061240
27. Hashemi Goradel N, Najafi M, Salehi E. Cyclooxygenase-2 in can-
cer: a review. J Cell Physiol. 2019;234(5):5683–5699.
28. Song Y, Zhao XP, Song K, Shang Z-J, Lee JW. Ephrin-A1 is
up-regulated by hypoxia in cancer cells and promotes angiogenesis
of HUVECs through a coordinated cross-talk with eNOS. PLoS One.
2013;8(9):e74464. doi:10.1371/journal.pone.0074464
29. Narayanan S, Gabriel E 2, Attwood K, Boland P, Nurkin S. Association
of clinicopathologic and molecular markers on stage-specific survival of
right versus left colon cancer.Clin Colorectal Cancer. 2018;17(4):e671–
e678. doi:10.1016/j.clcc.2018.07.001
30. Wang Y, Vnencak-Jones CL, Cates JM, Shi C. Deciphering elevated
microsatellite alterations at selected tetra/pentanucleotide repeats, micro-
satellite instability, and loss of heterozygosity in colorectal cancers. J Mol
Diagn. 2018;20(3):366–372. doi:10.1016/j.jmoldx.2018.02.001
31. Carethers JM, Koi M, Tseng-Rogenski SS. EMAST is a form of
microsatellite instability that is initiated by inflammation and mod-
ulates colorectal cancer progression. Genes (Basel). 2015;6
(2):185–205.
32. Koi M, Tseng-Rogenski SS, Carethers JM, et al. Inflammation-
associated microsatellite alterations: mechanisms and significance in
the prognosis of patients with colorectal cancer. World J Gastrointest
Oncol. 2018;10(1):1–14. doi:10.4251/wjgo.v10.i1.1
Casadei-Gardini et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Cancer Management and Research 2019:114368
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
82
.1
68
.1
3 
on
 1
3-
Ju
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Supplementary material
Cancer Management and Research Dovepress
Publish your work in this journal
Cancer Management and Research is an international, peer-reviewed
open access journal focusing on cancer research and the optimal use of
preventative and integrated treatment interventions to achieve improved
outcomes, enhanced survival and quality of life for the cancer patient.
The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use.
Visit http://www.dovepress.com/testimonials.php to read real quotes
from published authors.
Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal
Table S1 Patient characteristics (N=276)
CT+B arm
(N=133)
CT arm
(N=143)
n (%) n (%) p
Median age, years (IQR) 66 (58–72) 66 (57–74) 1.000
Gender
Female 52 (39.1) 60 (42.0)
Male 81 (60.9) 83 (58.0) 0.629
Performance status
(ECOG)
0 109 (82.0) 111 (77.6)
1–2 24 (18.0) 32 (22.4) 0.372
Tumor localization
Rectum 31 (23.3) 41 (28.7)
Colon 102 (76.7) 102 (71.3) 0.311
Stage at diagnosis
I–III 31 (24.0) 35 (26.1)
IV 98 (76.0) 99 (73.9) 0.697
Grade
1 3 (3.0) 9 (7.6)
2 65 (65.0) 73 (61.9)
3 32 (32.0) 36 (30.5) 0.413
CT regimen
FOLFOX4 82 (61.6) 89 (62.2)
FOLFIRI 51 (38.4) 54 (37.8) 0.921
KRAS status
Wild-type 70 (58.8) 74 (58.3)
Mutated 49 (41.2) 53 (41.7) 0.930
Prior cancer therapy
Surgery 100 (75.2) 104 (72.7) 0.642
Radiotherapy 13 (9.8) 13 (9.1) 0.846
Adjuvant chemotherapy 27 (20.3) 25 (17.5) 0.550
Abbreviations: CT, chemotherapy; B, bevacizumab; ECOG, Eastern Cooperative
Oncology Group.
Dovepress Casadei-Gardini et al
Cancer Management and Research 2019:11 submit your manuscript | www.dovepress.com
DovePress
4369
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
82
.1
68
.1
3 
on
 1
3-
Ju
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
